Skip to main content
< Back
About
About the conference
App
Organisers & Partners
Latest updates
Press room
Registration
Venue 22
About the venue
Rooms
Call for abstracts
Programme 22
Tracks 22
Speakers 22
Side events 22
Subscribe
days
hours
minutes
seconds
Comorbidity
Sessions
Wednesday, 23 November
10:50
Substance use, mental health and mental well-being: observations, interventions and recovery promotion
10:50
to
12:20
Networking zone 3 (N3)
Short communication session
Substance-induced psychosis: register-linkage research in Nordic countries
10:50
to
12:20
Knowledge market 2 (K2)
Structured session
15:00
Convergence in behavioural addictions
15:00
to
16:30
Main stage
Structured session
Substance use and mental health disorders in Europe: prevalence, models of care, and implementation in a challenging COVID-19 context
15:00
to
16:30
Knowledge market 2 (K2)
Structured session
Understanding relationships between substance use, mental health and mental illness: Session 1
15:00
to
16:30
Networking zone 2 (N2)
e-poster guided tour
16:50
Addiction and comorbidity over the lifespan: mechanisms and interventions
16:50
to
18:20
Central square 2 (C2)
Structured session
Impact and lessons learned in implementing and sustaining Needs-Based Planning models for substance use and mental health services and systems
16:50
to
18:20
Knowledge market 2 (K2)
Structured session
Thursday, 24 November
10:50
Substance use and trauma
10:50
to
12:20
Knowledge market 2 (K2)
Oral presentation session
15:00
Client-centered approaches
15:00
to
16:30
Central square 3 (C3)
Oral presentation session
Drug deaths: A social, structural and systems analysis
15:00
to
16:30
Knowledge market 1 (K1)
Structured session
Understanding relationships between substance use, mental health and mental illness: Session 2
15:00
to
16:30
Networking zone 2 (N2)
e-poster guided tour
Friday, 25 November
10:50
Substance use and prison
10:50
to
12:20
Central square 1 (C1)
Oral presentation session
Presentations
Wednesday, 23 November
10:50
Oral presentation
2. Characteristics of incident substance-induced psychosis compared to incident first episode psychosis. A nationwide register-linkage study
10:50
to
12:20
Knowledge market 2 (K2)
Pihla Sassi
Short communication
Association between cannabis use and mental health disorders in adolescents in Catalonia: results of a cohort study
10:50
to
12:20
Networking zone 3 (N3)
Regina Muñoz-Galán
Oral presentation
3. Relapse rate of substance-induced psychosis and associated risk factors. A nationwide registerlinkage study
10:50
to
12:20
Knowledge market 2 (K2)
Heidi Taipale
Short communication
Physical activity during treatment for substance use disorder: What a systematic review tells us
10:50
to
12:20
Networking zone 3 (N3)
Florence Piché
Oral presentation
4. Substance-induced psychosis and later schizophrenia or bipolar disorder: transition rates and the role of infections
10:50
to
12:20
Knowledge market 2 (K2)
Jørgen G. Bramness
Short communication
Drug use, anxiety and depression among people living in prison in Belgium
10:50
to
12:20
Networking zone 3 (N3)
Kim Fernandez
Oral presentation
5. Antipsychotic use and associating factors among persons with substance-induced psychosis and first-episode psychosis. A nationwide register-linkage study
10:50
to
12:20
Knowledge market 2 (K2)
Jeyaniroshan Jeyapalan
Short communication
The temporal association between frequency of methamphetamine use, depression, and anxiety in a community-recruited cohort of methamphetamine smokers
10:50
to
12:20
Networking zone 3 (N3)
Zoe Duncan
Short communication
Effectiveness of mental health warnings on tobacco packaging in people with and without common mental health conditions: an online randomised experiment
10:50
to
12:20
Networking zone 3 (N3)
Katherine Sawyer
Oral presentation
1. Annual incidence of substance-induced psychoses in Scandinavia from 2000 to 2016
10:50
to
12:20
Knowledge market 2 (K2)
Eline Borger Rognli
Short communication
A realist evaluation of greenspace programmes for improving mental health and supporting people with problem substance use
10:50
to
12:20
Networking zone 3 (N3)
Wendy Masterton
Short communication
Mental Health and Addiction Prevention for former refugees: We do it together
10:50
to
12:20
Networking zone 3 (N3)
Jannet De Jonge
15:00
e-poster
COVID-19 pandemic induces severe impact on substances administration and on aspects of psychosocial life of patients under methadone and buprenorphine maintenance treatment
15:00
to
16:30
Networking zone 2 (N2)
Vasilios Stavropoulos
Oral presentation
4. The dual diagnosis inpatient and outpatient treatment program in Ljubljana: practical implementatio
15:00
to
16:30
Knowledge market 2 (K2)
Nusa Segrec,
Andrej Kastelic
e-poster
Childhood trauma among patients with substance use disorder
15:00
to
16:30
Networking zone 2 (N2)
Sana Derouiche
Discussion
Discussion: Substance use and mental health disorders in Europe
15:00
to
16:30
Knowledge market 2 (K2)
Gabriele Fischer
e-poster
Association between Tramadol use disorder and depressive disorder in Oran, northwest of Algeria.
15:00
to
16:30
Networking zone 2 (N2)
Amel Kherraf
e-poster
Bridging the Gap in Violence Prevention and Mental Health Support through Culturally Relevant Community-Led Initiatives.
15:00
to
16:30
Networking zone 2 (N2)
Rita Gatonye
e-poster
A systematic review and meta-analyses of longitudinal studies on mood and anxiety symptoms following prescription opioid use.
15:00
to
16:30
Networking zone 2 (N2)
Janni Leung
e-poster
Vicarious trauma among nurses working in addiction services and the role of leadership: a European mixed methods study
15:00
to
16:30
Networking zone 2 (N2)
K. Nicki Annunziata
e-poster
Pharmacological treatment of the concurrence of substance use disorder and another mental disorder in Spain. Results of a national survey.
15:00
to
16:30
Networking zone 2 (N2)
Juan J. Fernández-Miranda
e-poster
Influence of gender on the prevalence and pharmacological treatment of the co-occurrence of substance use disorder and another mental disorder in Spain.
15:00
to
16:30
Networking zone 2 (N2)
Silvia Díaz-Fernández
Oral presentation
1. What do we mean by psychiatric comorbidity or dual disorders?
15:00
to
16:30
Knowledge market 2 (K2)
Marta Torrens
e-poster
Cognitive screening for long term substance use outcome in a cohort of patients with polysubstance use disorder
15:00
to
16:30
Networking zone 2 (N2)
Jens Hetland
Oral presentation
2. Impact of Covid19 on mental health and drug use: main findings from the EMCDDA trendspotter study
15:00
to
16:30
Knowledge market 2 (K2)
Franca Beccaria
e-poster
Anhedonia during recovery of polysubstance use
15:00
to
16:30
Networking zone 2 (N2)
Aleksander Erga
Oral presentation
3. Psychiatric comorbidity in the European countries: prevalence and models of care
15:00
to
16:30
Knowledge market 2 (K2)
Francina Fonseca
Oral presentation
1. Convergences in the psychology of behavioral addictions
15:00
to
16:30
Main stage
Matthias Brand
Oral presentation
2. Convergences in the neurobiology of behavioral addictions
15:00
to
16:30
Main stage
Marc N. Potenza
Oral presentation
3. Convergences in the treatment of behavioral addictions
15:00
to
16:30
Main stage
Susana Jiménez-Murcia,
Fernando Fernández-Aranda,
Roser Granero
Oral presentation
4. Convergences in behavioral addiction policies
15:00
to
16:30
Main stage
Sophia Achab
Discussion
Convergence in behavioural addictions
15:00
to
16:30
Main stage
Luke Clark
Oral presentation
0. Convergence in behavioural addictions: Introduction
15:00
to
16:30
Main stage
Zsolt Demetrovics
16:50
Oral presentation
2. Impact and lessons learned in the implementation of a NBP model across the province of Quebec, Canada
16:50
to
18:20
Knowledge market 2 (K2)
Joël Tremblay
Oral presentation
1. Implementation of a substance use NBP model in a Northern Region of Ontario- results and lessons learned
16:50
to
18:20
Knowledge market 2 (K2)
Stephanie Paquette
Oral presentation
1. First findings of an RCT on treatment of PTSD in addiction: simultaneous or sequential treatment with EMDR, Prolonged Exposure, Imaginary Rescripting
16:50
to
18:20
Central square 2 (C2)
Nathalie Faber
Oral presentation
3. Development and pilot testing an integrated mental health and substance use Needs-based Planning model: Lessons learned for local planning and model refinements
16:50
to
18:20
Knowledge market 2 (K2)
Brian Rush
Oral presentation
2. Older adults and alcohol use: negative affect, resilience, and alcohol use as interacting factors
16:50
to
18:20
Central square 2 (C2)
Yannick van Gils
Oral presentation
5. Focus on implementation processes, impacts to date and pros and cons of the sustainability of the Australian Mental Health model
16:50
to
18:20
Knowledge market 2 (K2)
Sandra Diminic
Oral presentation
3. Effectiveness of a digital alcohol moderation intervention as an add-on to depression treatment for young adults: findings of a pragmatic randomized controlled trial
16:50
to
18:20
Central square 2 (C2)
Maria J.E. Schouten
Oral presentation
4. Focus on implementation processes, impacts to date and pros and cons of the sustainability of the Auralian SU model model
16:50
to
18:20
Knowledge market 2 (K2)
Alison Ritter
Oral presentation
4. Illegal substance use during pregnancy: what do we know about risks and detoxification?
16:50
to
18:20
Central square 2 (C2)
Cleo L. Crunelle
Discussion
Strategic approach to service prioritization and resource allocation
16:50
to
18:20
Knowledge market 2 (K2)
Daniel Vigo
Thursday, 24 November
10:50
Oral presentation
The association between moral injury and cannabis use disorder among Israeli combat veterans: current state of knowledge and future directions
10:50
to
12:20
Knowledge market 2 (K2)
Daniel Feingold
Oral presentation
Alcohol and drug use among trauma patients with injuries of violence– results from the IDART study
10:50
to
12:20
Knowledge market 2 (K2)
Benedicte Jørgenrud
Oral presentation
addictive disorders and post-traumatic stress disorders
10:50
to
12:20
Knowledge market 2 (K2)
Léa Montagnier
Oral presentation
A novel trauma-focused psychological therapy for co-occurring substance use and PTSD among adolescents
10:50
to
12:20
Knowledge market 2 (K2)
Emma Barrett
15:00
e-poster
Antisocial personality disorder: A high risk of polydrug use?
15:00
to
16:30
Networking zone 2 (N2)
Ayoub Salhi
e-poster
Prescription Patterns on Patients with Dual Diagnosis: A Retrospective Inpatient Analysis
15:00
to
16:30
Networking zone 2 (N2)
Inês Pereira
e-poster
The war on time: an insight into the temporal relation between cannabis consumption and toxic psychosis
15:00
to
16:30
Networking zone 2 (N2)
Ana Soares
e-poster
Smoking-related health inequalities, tobacco smoking and substance use disorder.
15:00
to
16:30
Networking zone 2 (N2)
Mireia Graell Gabriel
e-poster
Program 'Eu e os Outros': Adaptation to the university context
15:00
to
16:30
Networking zone 2 (N2)
Mariana Montalvão
e-poster
Perception of the risk associated with drug use in patients with a previous episode of Cannabis-Induced Psychotic Disorder
15:00
to
16:30
Networking zone 2 (N2)
Maria Coelho
e-poster
Khat and neurobehavioral functions: a systematic review
15:00
to
16:30
Networking zone 2 (N2)
Manuel Jesús Ruiz Muñoz
e-poster
Group Intervention for Parents of People With Psychotic and Substance Use Disorders: A Qualitative Evaluation of appropriateness
15:00
to
16:30
Networking zone 2 (N2)
Karine Gaudreault
e-poster
How Attention Deficit Hyperactivity Disorder and Substance Use Disorder influence each other: A non-systematic literature review
15:00
to
16:30
Networking zone 2 (N2)
Catarina Oliveira
e-poster
Substance-Related Problems in Adolescents with ADHD-Diagnoses: The Importance of Self-Reported Conduct Problems
15:00
to
16:30
Networking zone 2 (N2)
Ove Heradstveit
Oral presentation
3. The role of Primary Care in the prevention of drug-related deaths: Patient and family member perspectives
15:00
to
16:30
Knowledge market 1 (K1)
Katie Colliver
Discussion
What can a social, structural and systems analysis tell us about drug-related deaths and what are the implications for policy and addiction science?
15:00
to
16:30
Knowledge market 1 (K1)
Anne Whittaker
Oral presentation
4. The role of Primary Care in the prevention of drug-related deaths: service provider perspectives
15:00
to
16:30
Knowledge market 1 (K1)
Betsy Thom
Oral presentation
5. Drug Policy and The Rise and Decline of Racial Stratification of Prescribing and Overdose Mortality
15:00
to
16:30
Knowledge market 1 (K1)
Brian Kelly
Oral presentation
1. Drug-related deaths among young people: a social, structural and systems autopsy
15:00
to
16:30
Knowledge market 1 (K1)
Aileen O'Gorman
Oral presentation
2. Drug-related deaths in prisons in England and Wales, 2015-2020: an examination of key trends and issues for policy and practice
15:00
to
16:30
Knowledge market 1 (K1)
Karen Duke
Oral presentation
Examining health care from the drug user perspective: what works, what doesn't and what needs to change
15:00
to
16:30
Central square 3 (C3)
Mary Ellen Harrod
Oral presentation
An Evaluation of the Co-Design of an Anti-Stigma Training Programme
15:00
to
16:30
Central square 3 (C3)
Sonam Prakashini Banka
Oral presentation
Once you’ve addressed your drinking, we’ll address your mental health': A qualitative exploration of patient and providers’ experiences of services for co-occurring heavy drinking and depression in North East England
15:00
to
16:30
Central square 3 (C3)
Amy O'Donnell
Oral presentation
Police officers’ attitudes and practices toward harm reduction services in Sweden – a qualitative study
15:00
to
16:30
Central square 3 (C3)
Johan Nordgren
Oral presentation
Who is using take-home naloxone? An examination of super-savers
15:00
to
16:30
Central square 3 (C3)
Desiree Eide
e-poster
The Clinical Course of Comorbid Substance Use Disorder and Attention Deficit/Hyperactivity Disorder: Protocol and Clinical Characteristics of the INCAS Study
15:00
to
16:30
Networking zone 2 (N2)
Johan Franck
Friday, 25 November
10:50
Oral presentation
Factors associated with mortality in The Norwegian Offender Mental Health and Addiction (NorMA)- cohort
10:50
to
12:20
Central square 1 (C1)
Torill Tverborgvik
Oral presentation
All cause and cause specific mortality among individuals imprisoned for driving under the influence of alcohol and drugs in Norway (2000-2016)
10:50
to
12:20
Central square 1 (C1)
Ragnhild Jamt
Oral presentation
The Impact of Co-Occurring Mental Health Problems on Referral to and Initiation of Treatment Among Youth Under Probation Supervision
10:50
to
12:20
Central square 1 (C1)
Steven Belenko
Oral presentation
(Ex-)inmates' substance use: a needs assessment based on semi-structured interviews
10:50
to
12:20
Central square 1 (C1)
Nicky Dirkx
Oral presentation
Prevalence of heroin drug use before and during imprisonment in Europe: results from a comprehensive literature review and analysis of prevalence data in six European countries
10:50
to
12:20
Central square 1 (C1)
Sara Mazzilli